



**FOR IMMEDIATE RELEASE**

**Fujirebio Diagnostics Contact:**

Maureen Miller  
JFK Communications, Inc.  
(609) 514-5117  
[mmiller@jfkhealth.com](mailto:mmiller@jfkhealth.com)

**Quest Diagnostics Contacts:**

Media Relations: (973) 520-2800  
Investor Relations: (973) 520-2900

**QUEST DIAGNOSTICS AND FUJIREBIO DIAGNOSTICS ANNOUNCE AVAILABILITY OF  
NEW FDA-CLEARED BLOOD-BASED TEST FOR OVARIAN CANCER**

**MALVERN, PA and MADISON, NJ, September 16, 2008** – Fujirebio Diagnostics, Inc. and Quest Diagnostics Incorporated (NYSE: DGX) today announced the launch of the HE4 test as an aid for monitoring recurrence of epithelial ovarian cancer. Quest Diagnostics' physician and hospital laboratory customers in the United States now can order tests for HE4, a new biomarker of ovarian cancer. Quest Diagnostics is the exclusive reference laboratory provider of the HE4 test in the U.S.

Fujirebio Diagnostics recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the HE4 assay to be used as an aid in the monitoring of recurrent or progressive disease in patients with epithelial ovarian cancer. In its application for FDA clearance, Fujirebio Diagnostics showed results of a recent study that evaluated HE4 testing in monitoring disease in patients diagnosed with ovarian cancer. HE4 test results in 354 sample pairs were compared to changes in disease status. Sixty percent of the patient samples or 76/126 exhibited a positive change in the HE4 value, which correlated with the progression of the disease. Three-quarters of patient samples or 171/228 had no significant change in value and correlated with no progression of disease. Total concordance was 70 percent or 247/354.

Ovarian cancer is the leading cause of death from gynecologic cancers in the U.S. and the fifth-leading cause of cancer deaths in women. There are an estimated 22,000 new cases of ovarian cancer diagnosed annually in the U.S. Women who are postmenopausal are at the greatest risk for this disease. Women have a one in 72 lifetime risk of developing ovarian cancer.

“Because ovarian cancer often recurs in women following treatment, physicians must periodically monitor their patients,” said Stephen C. Suffin, M.D., interim chief laboratory office and corporate medical director, clinical pathology, Quest Diagnostics. “As the first national commercial laboratory to offer HE4 and CA125 testing services, our goal is to give physicians access to both of these tests to aid their efforts to monitor women for recurrence.” Fujirebio Diagnostics is the manufacturer of the CA125 test which is cleared by the FDA for detecting residual ovarian carcinoma.

“We are pleased to collaborate with Quest Diagnostics to offer this important oncology diagnostic tool to a wider audience of U.S. oncology caregivers,” said Monte Wiltse, vice president of sales and marketing for Fujirebio Diagnostics. “By working with Quest Diagnostics, we can ensure physicians will have better access to recent and newly approved tests that are changing the landscape of oncology care.”

**About Fujirebio Diagnostics, Inc.**

Fujirebio Diagnostics, Inc. is a premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of *in-vitro* diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is a wholly owned subsidiary of Fujirebio Inc. Fujirebio Inc. is a leading healthcare company in Japan with a focus on diagnostics, and is a group company of Miraca Holdings. Fujirebio Diagnostics has a worldwide distribution network which enables physicians and patients to access its diagnostic products. For more information about Fujirebio Diagnostics, please call 610-240-3800 or visit [www.fdi.com](http://www.fdi.com).

**About Quest Diagnostics**

Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: [www.questdiagnostics.com](http://www.questdiagnostics.com).

###